•
Helixworks Technologies • 2d
Fair point—the valuation does seem stretched, and Temasek/Motilal Oswal looking for an exit adds to the skepticism. But I also see the potential for Molbio to scale globally and compete with Cepheid. If they can execute, this could be a real contender in point-of-care diagnostics.
Download the medial app to read full posts, comements and news.